09.23.26 -- What Strong Biotech IP Strategies Get Right And Where Weak Ones Break Down

Traditional, decentralized, and hybrid trial models each offer unique benefits. The right approach can strengthen recruitment, retention, data quality, and study success.

As PV complexity grows, manual oversight can slow teams down. Discover how automation improves KPI visibility, supports SLA compliance, and simplifies affiliate monitoring.

A $600 million manufacturing investment will bring 335 jobs to Sanford while expanding chemistry innovation, production and distribution capacity within North Carolina’s rapidly growing ecosystem.

A 2026 executive order is fast-tracking psychedelic therapies for depression, PTSD, and addiction. Understand what this regulatory shift means for your next clinical trial.

Bispecific antibodies (bsAbs) offer transformative therapeutic potential through dual-target engagement, but their complex structure presents significant manufacturing challenges.

Policy shifts are reshaping PBM oversight, driving transparent drug‑pricing tools, and influencing global responses that affect affordability, access, and future pharma development.